beta-neo-endorphin has been researched along with morphiceptin in 1 studies
| Studies (beta-neo-endorphin) | Trials (beta-neo-endorphin) | Recent Studies (post-2010) (beta-neo-endorphin) | Studies (morphiceptin) | Trials (morphiceptin) | Recent Studies (post-2010) (morphiceptin) |
|---|---|---|---|---|---|
| 30 | 0 | 0 | 139 | 0 | 12 |
| Protein | Taxonomy | beta-neo-endorphin (IC50) | morphiceptin (IC50) |
|---|---|---|---|
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0566 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.32 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Macdonald, RL; Werz, MA | 1 |
1 other study(ies) available for beta-neo-endorphin and morphiceptin
| Article | Year |
|---|---|
Dynorphin and neoendorphin peptides decrease dorsal root ganglion neuron calcium-dependent action potential duration.
Topics: Action Potentials; Animals; beta-Endorphin; Calcium; Cells, Cultured; Dose-Response Relationship, Drug; Dynorphins; Endorphins; Enkephalin, Leucine; Ganglia, Spinal; Ion Channels; Mice; Naloxone; Protein Precursors; Receptors, Opioid; Sodium; Time Factors | 1985 |